英国MHRA重磅批准Wegovy 7.2mg“超高剂量”版本英国药品和保健品监管局(MHRA)刚刚批准了诺和诺德(Novo Nordisk)旗下重磅减肥药Wegovy的最新规格——7.2mg注射液。制造商诺和诺德证实,这款被称为“三倍强度”的新剂型预计将于2026年正式在英国上市。数据亮点:直逼替尔泊肽此次获批的7.2mg版本,其剂量是目前NHS标准最高剂量(2.4mg)的3倍。临床试验数据展现了...
Source Link英国MHRA重磅批准Wegovy 7.2mg“超高剂量”版本英国药品和保健品监管局(MHRA)刚刚批准了诺和诺德(Novo Nordisk)旗下重磅减肥药Wegovy的最新规格——7.2mg注射液。制造商诺和诺德证实,这款被称为“三倍强度”的新剂型预计将于2026年正式在英国上市。数据亮点:直逼替尔泊肽此次获批的7.2mg版本,其剂量是目前NHS标准最高剂量(2.4mg)的3倍。临床试验数据展现了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.